Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer - PubMed (original) (raw)
Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer
Manu Anantpadma et al. J Antimicrob Chemother. 2010 May.
Abstract
Background: Japanese encephalitis virus (JEV) has a significant impact on public health throughout Asia, and there is a pressing need for development of new therapeutics against it.
Methods: Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are antisense agents that enter cells readily and interfere with gene expression. Four PPMOs, targeting various locations in the JEV genome, were evaluated for antiviral activity against JEV in cultured cells and the mouse model of JEV infection.
Results: A PPMO (P10882) targeting the JEV 3' cyclization sequence (3'CSI) had significant antiviral activity in Vero (epithelial), Neuro2A (neuronal) and J774E (macrophage) cells at concentrations that were not cytotoxic. P10882 added before infection suppressed JEV replication to an undetectable level in Vero cells and produced a 93% and 66% reduction in titre in J774E and Neuro2A cells, respectively, when measured at 24 h post-infection. In uninfected cells, fluorescein-labelled PPMOs entered J774E cells most efficiently, followed by Vero and Neuro2A cells. The antiviral effect of P10882 was also demonstrated in vivo, where 60%-80% of 1-week-old mice treated intracerebrally with a 20 mg/kg dose of P10882 every 12 h for 5 days were protected from a lethal dose of JEV and showed an undetectable level of virus in brain tissue at 2 days post-infection.
Conclusions: P10882, which targets sequence that is highly conserved across members of the JEV serocomplex, was previously shown to be effective in a mouse model of West Nile disease, and represents a candidate antiviral agent against members of the JEV serocomplex.
Figures
Figure 1
PPMO target locations in the JEV genome, and sequence conservation at the 3′CSI region. (a) Diagram showing the secondary structure of 5′- and 3′-UTRs of JEV genomic RNA, as predicted by the Mfold program. The PPMO target sequences are indicated with names, lines and arrows. The nucleotides of the AUG translation initiation codon are circled. Numbers in the lighter font refer to the nucleotide position in the JEV genome. (b) Sequence conservation at the P10882 PPMO target site. Alignments of GenBank sequences for four members of the JEV serocomplex in the 3′CSI region are shown. The 3′CSI core sequence location and the nucleotide positions in the JEV genome are indicated below and above the alignment, respectively. Virus abbreviations followed by the GenBank accession number: JEV, Japanese encephalitis virus (NC_001437); WNV, West Nile virus (NC_009942); SLEV, St Louis encephalitis virus (NC_007580); MVEV, Murray Valley encephalitis virus (NC_000943).
Figure 2
PPMO-mediated inhibition of JEV replication in cultured cells. Cell monolayers were treated with 10 µM PPMO for 3 h followed by infection with JEV at an moi of 0.1. Aliquots of culture supernatant were removed at 24 and 36 h p.i. and extracellular virus titrated by plaque assay. All experiments were carried out in triplicate. Mean titres from PPMO-treated cells were compared with those from vehicle-treated cells. The statistical significance of difference in titres was determined by the paired _t_-test; an asterisk indicates P < 0.05.
Figure 3
Dose-dependent inhibition of JEV replication by the P10882 PPMO. Vero cell monolayers were treated with increasing concentrations of PPMO for 3 h followed by infection with JEV at an moi of 0.1. Scrambled PPMO (PSCR) at a concentration of 10 µM was used as a control. Aliquots of culture supernatant were removed at 24 h p.i. and extracellular virus titrated by plaque assay. All experiments were carried out in triplicate. Mean titres from PPMO-treated cells were compared with those from vehicle-treated cells. The statistical significance of difference in titres was determined by the paired Student's _t_-test; an asterisk indicates P < 0.05.
Figure 4
PPMO uptake by three types of cultured cells. Cell monolayers were incubated with 10 µM PSCR–Fl PPMO for 3 h followed by washing. The top panels show cells visualized by phase contrast (left-hand panels) and fluorescence microscopy (right-hand panels). In a parallel experiment PSCR–Fl-treated cells were washed and resuspended in culture medium followed by flow cytometric estimation of the fluorescing cells and the fluorescence intensity (bottom left-hand panel) as described in the Materials and methods section. The bottom right-hand panel shows the fold increase in the mean fluorescence intensity (MFI) of cells following treatment with PSCR–Fl. This figure appears in colour in the online version of JAC and in black and white in the printed version of JAC.
Figure 5
PPMO toxicity in mice. Groups of 8-day-old BALB/c mice (n = 8) were injected intracerebrally with a 10–50 mg/kg dose of P10882, as indicated, every 12 h for 8 days and observed for mortality or other signs of toxicity. None of the mice that received up to a 25 mg/kg dose of PPMO showed any apparent signs of toxicity. Survival rates for the various treatment groups are shown by a Kaplan–Meier chart.
Figure 6
PPMO-mediated protection of JEV-infected mice. Groups of 1-week-old BALB/c mice (n = 8) were injected with the indicated amounts of PPMO and infected with 100 pfu of JEV 5 h later. Both PPMO and virus were administered intracerebrally. In addition, mice received the indicated dose of PPMO every 12 h after infection for 5 days. Additional control groups included mice receiving JEV and an initial treatment with vehicle (no PPMO) or uninfected mice receiving P10882 every 12 h for 5 days. Mice mortality was monitored for 10 days. The top three panels show results of the experiment done in triplicate.
Figure 7
JEV titres in mice brain following PPMO treatment. One-week-old BALB/c mice (n = 8) were treated with a 20 mg/kg dose of PPMO as described in the Materials and methods section. Brain tissue was harvested at different timepoints and homogenized for plaque assays. JEV titres in individual mouse brains are shown. The dotted line shows the virus titre assay limit of 50 pfu/mL. Points below the dotted line indicate an undetectable virus titre. Bars indicate the mean titre in a group.
Similar articles
- siRNA-mediated suppression of Japanese encephalitis virus replication in cultured cells and mice.
Anantpadma M, Vrati S. Anantpadma M, et al. J Antimicrob Chemother. 2012 Feb;67(2):444-51. doi: 10.1093/jac/dkr487. Epub 2011 Nov 23. J Antimicrob Chemother. 2012. PMID: 22114132 - Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model.
Shi Z, Wei J, Deng X, Li S, Qiu Y, Shao D, Li B, Zhang K, Xue F, Wang X, Ma Z. Shi Z, et al. Virol J. 2014 Jan 23;11:10. doi: 10.1186/1743-422X-11-10. Virol J. 2014. PMID: 24456815 Free PMC article. - Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis.
Nazmi A, Dutta K, Basu A. Nazmi A, et al. PLoS Negl Trop Dis. 2010 Nov 23;4(11):e892. doi: 10.1371/journal.pntd.0000892. PLoS Negl Trop Dis. 2010. PMID: 21124882 Free PMC article. - Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.
Stein DA. Stein DA. Curr Pharm Des. 2008;14(25):2619-34. doi: 10.2174/138161208786071290. Curr Pharm Des. 2008. PMID: 18991679 Review. - Antioxidants: potential antiviral agents for Japanese encephalitis virus infection.
Zhang Y, Wang Z, Chen H, Chen Z, Tian Y. Zhang Y, et al. Int J Infect Dis. 2014 Jul;24:30-6. doi: 10.1016/j.ijid.2014.02.011. Epub 2014 Apr 26. Int J Infect Dis. 2014. PMID: 24780919 Review.
Cited by
- Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Okamoto S, Echigoya Y, Tago A, Segawa T, Sato Y, Itou T. Okamoto S, et al. Int J Mol Sci. 2023 Oct 2;24(19):14846. doi: 10.3390/ijms241914846. Int J Mol Sci. 2023. PMID: 37834294 Free PMC article. - Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines.
Srivastava KS, Jeswani V, Pal N, Bohra B, Vishwakarma V, Bapat AA, Patnaik YP, Khanna N, Shukla R. Srivastava KS, et al. Vaccines (Basel). 2023 Mar 27;11(4):742. doi: 10.3390/vaccines11040742. Vaccines (Basel). 2023. PMID: 37112654 Free PMC article. Review. - Antiviral drug research for Japanese encephalitis: an updated review.
Joe S, Salam AAA, Neogi U, N NB, Mudgal PP. Joe S, et al. Pharmacol Rep. 2022 Apr;74(2):273-296. doi: 10.1007/s43440-022-00355-2. Epub 2022 Feb 19. Pharmacol Rep. 2022. PMID: 35182390 Free PMC article. Review. - Artificial MicroRNA-Mediated Inhibition of Japanese Encephalitis Virus Replication in Neuronal Cells.
Sharma H, Tripathi A, Kumari B, Vrati S, Banerjee A. Sharma H, et al. Nucleic Acid Ther. 2018 Dec;28(6):357-365. doi: 10.1089/nat.2018.0743. Epub 2018 Nov 20. Nucleic Acid Ther. 2018. PMID: 30457923 Free PMC article. - Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.
Nan Y, Zhang YJ. Nan Y, et al. Front Microbiol. 2018 Apr 20;9:750. doi: 10.3389/fmicb.2018.00750. eCollection 2018. Front Microbiol. 2018. PMID: 29731743 Free PMC article. Review.
References
- Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol. 2002;267:171–94. - PubMed
- Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187–95. - PubMed
- Stein D, Foster E, Huang SB, et al. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 1997;7:151–7. - PubMed
- Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release. 2006;116:304–13. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources